Immunotherapy for Non-Hodgkin Lymphoma — Which Kind Applies to Which Subtype

Yes, but usually not the kind people mean. Most patients with non-Hodgkin lymphoma are not candidates for checkpoint immunotherapy. Its role here is narrow. The immune-based treatment most B-cell lymphoma patients receive is antibody therapy, which is a different class of drug and has been standard for over two decades.

That distinction is the single most useful thing on this page. When a news report says immunotherapy, it almost always means a checkpoint inhibitor. When a haemato-oncologist says immunotherapy in a lymphoma clinic, they usually mean an antibody aimed at a marker on the surface of the lymphoma cell. The word is the same. The treatments are not.

Non-Hodgkin lymphoma is also not one disease. The WHO classification recognises more than sixty subtypes, some fast-growing, some so slow they are watched rather than treated. A plan that is correct for one can be wrong for another. Which immune-based treatment applies is read off the biopsy and immunohistochemistry report, not off the umbrella term.

Personal history narrows it further. Active autoimmune disease, a previous organ transplant, ongoing high-dose steroids, or long-standing hepatitis B all change the calculation, because immune-based treatment works by altering how the immune system behaves rather than by attacking the tumour directly.

Nothing on this page decides eligibility. That rests on the subtype, the stage, previous treatment and overall fitness, read together by a haemato-oncologist.

Antibody therapy applies to most common B-cell subtypes. Checkpoint blockade applies to very few. B-cell lymphomas carry surface markers an antibody can bind, which is why antibody treatment became standard there. T-cell lymphomas lack that particular target and follow different pathways.

Subtype groups only. Individual eligibility depends on the full histopathology and immunohistochemistry report, the stage, and what has already been given. No product is named on this page, deliberately.

Almost always antibody therapy. An antibody attaches directly to a marker on the lymphoma cell and flags it for destruction. Checkpoint treatment does something different: it releases a brake on your own T cells. The first is standard in most B-cell subtypes. The second is reserved for a few defined situations.

If you take one thing from this page, take the question. Ask the treating team which of these two has been prescribed, and write the answer down. It changes what to watch for at home, what the first cycle will feel like, and which side effects are worth an urgent call. Antibody Therapy for Blood Cancers: The Original Immunotherapy sets out how that class works in more detail.

For most common B-cell subtypes, at the very start. Antibody therapy is part of the first treatment given, combined with chemotherapy from cycle one. Checkpoint treatment sits much later and only in the few subtypes where guidelines list it. CAR-T and transplant belong to the relapsed setting, at designated centres.

• Antibody and chemotherapy treatment — given at CION as day care at our centres. You come in, are observed during and after the infusion, and go home the same day. An overnight stay is not part of a routine cycle.
• Tumour board and written second opinion — given at CION. Medical, surgical and radiation oncologists review the case together. The subtype, the plan and the reasoning are explained to you before the first cycle, not after it.
• Response-assessment PET-CT — coordinated, not owned. Scans are arranged at partner imaging centres and reported back into the plan. They are scheduled at set points rather than on request.
• CAR-T cell therapy — not provided at CION. CION Cancer Clinics does not administer, stock or manufacture CAR-T or any other cell therapy. Where it is genuinely on the table for a diagnosis, referral to an accredited cell-therapy centre is the right next step and we will say so.
• Stem cell transplant — not performed at CION. Transplant is referred to a designated transplant centre. We can prepare the record, explain what the pathway will demand, and give a second opinion on the plan you have already been offered.
• Cost, stated openly. Aarogyasri, CGHS, ECHS and cashless insurance are handled at our centres, and scheme ceilings are explained before treatment begins. Any figure discussed is indicative, as of August 2026, and no price is quoted against a named product anywhere on this site.

The first dose is the one to prepare for. Infusion reactions with antibody therapy cluster in the first infusion, which is why it runs slower and is watched more closely than every cycle after it. Infusion Reactions With Antibody Therapy: The First Dose covers what that day actually looks like and what to tell the nurse.

Survivorship is where the honest answer is the least satisfying. Long-term data for the newer immune-based treatments is genuinely immature, simply because they have not been in use long enough. Fertility, thyroid and heart monitoring, vaccination timing, and how low antibody levels after B-cell directed treatment are followed up are all reasonable things to ask about at the start, not years later. A team that tells you where the evidence runs out is more useful than one that fills the gap with reassurance.

• The class most non-Hodgkin lymphoma patients are actually given is explained in full in Antibody Therapy for Blood Cancers: The Original Immunotherapy.
• If the first cycle is the immediate worry, Infusion Reactions With Antibody Therapy: The First Dose sets out what happens, why it is front-loaded, and what to report during the infusion.
• For patients in their twenties and thirties, Immunotherapy for Lymphoma in Young Adults: Late Effects covers fertility, long-term monitoring and what is still unknown.
• For how immune-based treatment is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to a specific lymphoma diagnosis? Book a free consultation and a medical oncologist will go through the reports with you.